SOLARIMS
Solriamfetol
MS, type not stated · phase 2 · 46 participants
Main results due Dec 2026
Symptoms
Assembled by software from public sources.
Solriamfetol
MS, type not stated · phase 2 · 46 participants
Main results due Dec 2026
Symptoms
| Area | Due | Trial | Tests | Type of MS | Phase | Participants |
|---|---|---|---|---|---|---|
| 2028 | ||||||
| Symptoms | Jan 2028 | Arbaclofen, phase 3 | Arbaclofen | MS, type not stated | phase 3 | 442 |
| Symptoms | Jan 2028 | Neuromodulation device, phase 2 | Neuromodulation device | Relapsing and progressive MS | phase 2 | 170 |